Article
Duluth, GA-Novartis AG is cutting up to 170 jobs from its ophthalmics business and moving what's left of the operation to New Jersey, where it will join Novartis Pharmaceuticals Corp. (NPC) as a separate business unit.
Study reveals growing treatment burden of retinal diseases in Finland
California dreaming: 2025 Glaucoma 360 brings celebration, innovation, and education to San Francisco
Advanced therapies for retinal vascular diseases
Connect, learn, and innovate in a family-friendly atmosphere: What to expect at EnVision Summit 2025
4DMT publishes preclinical data demonstrating the potential of the Therapeutic Vector Evolution (TVE) platform
Curacle presents results of its phase 2a clinical trial of CU06 for DME